Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment

Acta Ophthalmologica

Volumn 91, Issue 7, 2013, Pages

  Reznicek, Lukas ^a   Cserhati, Sarah ^a   Seidensticker, Florian ^a   Liegl, Raffael ^a   Kampik, Anselm ^a   Ulbig, Michael ^a   Neubauer, Aljoscha S ^a   Kernt, Marcus ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

anti vascular endothelial growth factor; diabetic macular edema; diabetic retinopathy; imaging; microperimetry; optical coherence tomography; Ranibizumab

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; BLOCKING PHENOMENON; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CORRELATION ANALYSIS; CYST SIZE; DIABETIC MACULAR EDEMA; EYE INJURY; EYE LAYER INTEGRITY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; MICROPERIMETRIC MACULAR SENSITIVITY; MORPHOLOGY; OCULUS SINISTER CONTINUITY; PREVALENCE; PRIORITY JOURNAL; RETINA BIPOLAR GANGLION CELL; RETINA INNER NUCLEAR LAYER CYST; RETINA OUTER NUCLEAR LAYER CYST; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; VISION; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; IMAGING; MICROPERIMETRY; OPTICAL COHERENCE TOMOGRAPHY; RANIBIZUMAB;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 84885947603     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12153     Document Type: Article

References (42)

1. Aiello LP, Avery RL, Arrigg PG, et al., (1994): Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487.
2. Alasil T, Keane PA, Updike JF, Dustin L, Ouyang Y, Walsh AC, &, Sadda SR, (2010): Relationship between optical coherence tomography retinal parameters and visual acuity in diabetic macular edema. Ophthalmology 117: 2379-2386.
3. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH, Liou GI, &, Caldwell RW, (2005): Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets 6: 511-524.
4. Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K, Hoogwerf BJ, &, Miller D, (1996): Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 114: 1079-1084.
5. Chun DW, Heier JS, Topping TM, Duker JS, &, Bankert JM, (2006): A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113: 1706-1712.
6. Deak GG, Bolz M, Ritter M, Prager S, Benesch T, &, Schmidt-Erfurth U, (2010): A systematic correlation between morphology and functional alterations in diabetic macular edema. Invest Ophthalmol Vis Sci 51: 6710-6714.
7. Deissler HL, Deissler H, &, Lang GE, (2011): Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells. Br J Ophthalmol 95: 1151-1156.
8. Derevjanik NL, Vinores SA, Xiao WH, Mori K, Turon T, Hudish T, Dong S, &, Campochiaro PA, (2002): Quantitative assessment of the integrity of the blood-retinal barrier in mice. Invest Ophthalmol Vis Sci 43: 2462-2467.
9. Elman MJ, Bressler NM, Qin H, et al., (2011): Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 118: 609-614.
10. Ferris FL 3rd, &, Patz A, (1984): Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol 28 (Suppl): 452-461.
11. Gillies M, (2009): Diabetic macular edema. Ophthalmology 116: 595; author reply 596-597.
12. Grant MB, Afzal A, Spoerri P, Pan H, Shaw LC, &, Mames RN, (2004): The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs 13: 1275-1293.
13. Jivrajka RV, Kim JK, Fink W, Sadun AA, &, Sebag J, (2009): Quantitative analysis of central visual field defects in macular edema using three-dimensional computer-automated threshold Amsler grid testing. Graefes Arch Clin Exp Ophthalmol 247: 165-170.
14. Kempen JH, O'Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, Taylor HR, &, Hamman RF, (2004): The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 122: 552-563.
15. Kim M, Lee P, Kim Y, Yu SY, &, Kwak HW, (2011): Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema. Ophthalmologica 226: 138-144.
16. Kunisaki M, Bursell SE, Clermont AC, et al., (1995): Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am J Physiol 269: E239-E246.
17. Kurashige Y, Tsujikawa A, Murakami T, Miyamoto K, Ogino K, Muraoka Y, &, Yoshimura N, (2012): Changes in visual acuity and foveal photoreceptor integrity in eyes with chronic cystoid macular edema associated with retinal vein occlusion. Retina 32: 792-798.
18. Lee SJ, Kim ET, &, Moon YS, (2011): Intravitreal bevacizumab alone versus combined with macular photocoagulation in diabetic macular edema. Korean J Ophthalmol 25: 299-304.
19. Maar N, Tittl M, Stur M, Zajic B, &, Reitner A, (2001): A new colour vision arrangement test to detect functional changes in diabetic macular oedema. Br J Ophthalmol 85: 47-51.
20. Massin P, Bandello F, Garweg JG, et al., (2010): Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33: 2399-2405.
21. Mathews MK, Merges C, McLeod DS, &, Lutty GA, (1997): Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy. Invest Ophthalmol Vis Sci 38: 2729-2741.
22. Mitchell P, Bandello F, Schmidt-Erfurth U, et al., (2011): The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118: 615-625.
23. Morigi M, Angioletti S, Imberti B, et al., (1998): Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-κB-dependent fashion. J Clin Invest 101: 1905-1915.
24. Moss SE, Klein R, &, Klein BE, (1998): The 14-year incidence of visual loss in a diabetic population. Ophthalmology 105: 998-1003.
25. Murakami T, Nishijima K, Akagi T, Uji A, Horii T, Ueda-Arakawa N, Muraoka Y, &, Yoshimura N, (2012): Optical coherence tomographic reflectivity of photoreceptors beneath cystoid spaces in diabetic macular edema. Invest Ophthalmol Vis Sci 53: 1506-1511.
26. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, Abraham P, &, Campochiaro PA, (2009): Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology 116: 2175-2181 e2171.
27. Nguyen QD, Shah SM, Khwaja AA, et al., (2010): Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 117: 2146-2151.
28. Nguyen QD, Brown DM, Marcus DM, et al., (2012): Ranibizumab for Diabetic Macular Edema: results from 2 Phase III Randomized Trials: RISE and RIDE. Ophthalmology 119: 789-801.
29. Nishikawa T, Edelstein D, Du XL, et al., (2000): Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787-790.
30. Nittala MG, Konduru R, Ruiz-Garcia H, &, Sadda SR, (2011): Effect of OCT volume scan density on thickness measurements in diabetic macular edema. Eye (Lond) 25: 1347-1355.
31. Peng S, Adelman RA, &, Rizzolo LJ, (2010): Minimal effects of VEGF and anti-VEGF drugs on the permeability or selectivity of RPE tight junctions. Invest Ophthalmol Vis Sci 51: 3216-3225.
32. Rohrschneider K, Springer C, Bultmann S, &, Volcker HE, (2005): Microperimetry-comparison between the micro perimeter 1 and scanning laser ophthalmoscope-fundus perimetry. Am J Ophthalmol 139: 125-134.
33. Sander B, Larsen M, Moldow B, &, Lund-Andersen H, (2001): Diabetic macular edema: passive and active transport of fluorescein through the blood-retina barrier. Invest Ophthalmol Vis Sci 42: 433-438.
34. Sawa M, Gomi F, Toyoda A, Ikuno Y, Fujikado T, &, Tano Y, (2006): A microperimeter that provides fixation pattern and retinal sensitivity measurement. Jpn J Ophthalmol 50: 111-115.
35. Shin HJ, Lee SH, Chung H, &, Kim HC, (2011): Association between photoreceptor integrity and visual outcome in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 250: 61-70.
36. Sukha AY, &, Rubin A, (2009): High, medium, and low contrast visual acuities in diabetic retinal disease. Optom Vis Sci 86: 1086-1095.
37. Wang J, Xu X, Elliott MH, Zhu M, &, Le YZ, (2010): Muller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage. Diabetes 59: 2297-2305.
38. Wautier JL, &, Guillausseau PJ, (2001): Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 27: 535-542.
39. Wolfensberger TJ, &, Gregor ZJ, (2010): Macular edema-rationale for therapy. Dev Ophthalmol 47: 49-58.
40. Wu PC, Lai CH, Chen CL, &, Kuo CN, (2012): Optical coherence tomographic patterns in diabetic macula edema can predict the effects of intravitreal bevacizumab injection as primary treatment. J Ocul Pharmacol Ther 28: 59-64.
41. Yilmaz T, Cordero-Coma M, Gallagher MJ, &, Teasley LA, (2011): Systematic review of intravitreal bevacizumab injection for treatment of primary diabetic macular oedema. Acta Ophthalmol 89: 709-717.
42. Zechmeister-Koss I, &, Huic M, (2012): Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review. Br J Ophthalmol 96: 167-178.